



Bio-Rad  
Laboratories

3, boulevard Raymond Poincaré  
92430 Marnes-la-Coquette France  
Téléphone : +33 (0) 1 47 95 60 00  
Fax : +33 (0) 1 47 41 91 33

Ref. FSCA 03-17 IDD

Marnes-la-Coquette, March 24<sup>th</sup> 2017

## URGENT FIELD SAFETY NOTICE

This information is intended for the end user of this product  
If you are not the end user, please forward this information to the appropriate laboratory personnel

**Subject:** URGENT Field Safety Notice – Monolisa™ HCV Ag-Ab ULTRA V2 assay  
Code Number 72561(1 plate - 96 tests) - 72562 (5 plates - 480 tests)

Dear Valued Customer,

Please read carefully the urgent **Field Safety Notice** regarding the product Monolisa HCV Ag-Ab ULTRA V2 assay code number 72561 (1 plate - 96 tests) - 72562 (5 plates - 480 tests).

### Product Details

Product	Code number	Lot number	Expiry date
Monolisa HCV Ag-Ab ULTRA V2 assay (1 plate - 96 tests)	72561	6J0029	2018/02/15
		6K0030	2018/02/28
		6K0031	2018/03/15
		6M0032	2018/04/15
		7A0033	2018/05/30
Monolisa HCV Ag-Ab ULTRA V2 assay (5 plates - 480 tests)	72562	6J0533	2018/02/15
		6K0534	2018/02/28
		6K0535	2018/03/15
		6M0536	2018/04/15

Table 1\_List of affected Lots

## Description of the issue

We have noticed a decrease of all Optical Densities (OD) values for tested samples and controls. This could result in plate invalidation. The lots affected by this issue are listed in table 1.

The phenomenon which causes a global decrease of all OD values appears some months after the manufacturing release of the lots. The reconstituted Antigen Positive Control - R5 (peptide in synthetic basis) is more impacted by the decrease of OD values and results in run invalidation when its OD becomes lower than 0.5. However, since final results (ratios) are not impacted, there is no risk of erroneous result.

The R6 reagent (Conjugate 1 - Mouse biotinylated monoclonal antibodies against capsid HCV antigen) has been identified as the major cause of this decrease of OD values. We are currently conducting deep investigations to determine with precision the root cause of this phenomenon.

As the root cause is not yet fully identified we will supply temporarily new batches with a reduced shelf life in limited quantities. We have performed stability studies on these new lots to demonstrate the conformity of the kit performance until their new expiry date.

## Impact on the patient

**Since final results (ratios) are not impacted, there is no risk for patient.**

Nevertheless considering the potential delay to results generated by this issue if your laboratory does not have an alternative method, we have decided to communicate through this Field Safety Notice to help you manage this difficult situation.

## Advise on action to be taken by the user

By consequence of this notification, we ask you:

- To continue to use kits and lots in table 1 as long as the validation criteria are met (refer to product package insert (section 7.5) for detailed instructions):
  - 1) For the negative control R3:  $O.D. < cut\ off \times 0.6$
  - 2) For the antibodies positive control R4:  $0.800 \leq Mean\ O.D. \leq 2.700$
  - 3) For the working solution R5:  $O.D. > 0.500$
- To stop using kits of lots in table 1 if validation criteria failed. In that case, discard the kit, fill the **Annex 1** and return it to your customer service to obtain replacement kits.

Note: If you would like to consider other alternative solutions, please contact our local representative.

We would like to inform you that our Notified Body and the European Competent Authorities are aware about this notification.

We sincerely apologize for the inconvenience, and remain at your disposal for any further information.

Please forward it to whomever it may concern.

